AM | Ecolab present the event dedicated to the essential update to ensure the proper application of the Contamination Control Strategy in the cleaning and disinfection processes of classified environments.
Register Now
Agenda
- Case Study: Contamination control assessment cleaning and disinfection
- This presentation explores the principles of Contamination Control Strategy (CCS) in the pharmaceutical industry, with a focus on cleaning and disinfection processes. Key elements such as microbial and particulate contamination and ensuring sterility are covered: a case study related to residue management and material transfer processes in a sterile pharmaceutical production, emphasizing protective measures and effective disinfection techniques.
- Assessment and management of disinfectant residues in the cleanroom (theoretical and practical session)
-
- Considering the revised version ofEudraLex Annex 1 Volume 4, published in August 2022, waste management has gained more importance, with references in four different sections of the document. Specifically, in the "Disinfection" section, paragraph 4.33 states: "Cleaning programs should effectively remove disinfectant residues." This presentation demonstrates how visual inspection (visual inspection) alone may not be sufficient for proper residue management and introduces an analytical method published by Ecolab for detecting disinfectant residues on a surface and its application for verifying the effectiveness of rinsing techniques.
- Workshop: Material Transfer (theoretical and practical session)
- A practical demonstration on the importance of using the correct packaging cleaning technique through the proper use of wipes during the material transfer process, respecting class jumps; here, effective methods for removing contamination from packaging are examined.
- Addressing the Challenge of Mould in GMP Environments
- Fungal and yeast contamin ation in contamination-controlled environments can pose a significant challenge to drug manufacturing, as it carries the risk of compromising the quality of the finished product and patient safety. Understanding its complexity, including the major strains of interest, is essential to implementing effective control measures.This presentation discusses the morphology of fungi and yeasts , the possible sources of contamination, the risks and challenges they pose, and the need to structure a system of preventive and corrective actions (CAPA plan) that can avoid regulatory noncompliance issues.
